321 related articles for article (PubMed ID: 30266498)
1. Weighted gene co-expression network analysis and connectivity map identifies lovastatin as a treatment option of gastric cancer by inhibiting HDAC2.
Zhang L; Kang W; Lu X; Ma S; Dong L; Zou B
Gene; 2019 Jan; 681():15-25. PubMed ID: 30266498
[TBL] [Abstract][Full Text] [Related]
2. Suberoylanilide hydroxamic acid enhances the antitumor activity of oxaliplatin by reversing the oxaliplatin‑induced Src activation in gastric cancer cells.
Zhou C; Ji J; Shi M; Yang L; Yu Y; Liu B; Zhu Z; Zhang J
Mol Med Rep; 2014 Nov; 10(5):2729-35. PubMed ID: 25199623
[TBL] [Abstract][Full Text] [Related]
3. Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell line.
Yagi Y; Fushida S; Harada S; Kinoshita J; Makino I; Oyama K; Tajima H; Fujita H; Takamura H; Ninomiya I; Fujimura T; Ohta T; Yashiro M; Hirakawa K
J Exp Clin Cancer Res; 2010 Nov; 29(1):149. PubMed ID: 21080974
[TBL] [Abstract][Full Text] [Related]
4. Identification of HDAC9 as a viable therapeutic target for the treatment of gastric cancer.
Xiong K; Zhang H; Du Y; Tian J; Ding S
Exp Mol Med; 2019 Aug; 51(8):1-15. PubMed ID: 31451695
[TBL] [Abstract][Full Text] [Related]
5. Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
Alzoubi S; Brody L; Rahman S; Mahul-Mellier AL; Mercado N; Ito K; El-Bahrawy M; Silver A; Boobis A; Bell JD; Hajji N
Oncotarget; 2016 Jul; 7(28):44505-44521. PubMed ID: 27283986
[TBL] [Abstract][Full Text] [Related]
6. Targeted inactivation of HDAC2 restores p16INK4a activity and exerts antitumor effects on human gastric cancer.
Kim JK; Noh JH; Eun JW; Jung KH; Bae HJ; Shen Q; Kim MG; Chang YG; Kim SJ; Park WS; Lee JY; Borlak J; Nam SW
Mol Cancer Res; 2013 Jan; 11(1):62-73. PubMed ID: 23175521
[TBL] [Abstract][Full Text] [Related]
7. Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells.
Chang H; Rha SY; Jeung HC; Jung JJ; Kim TS; Kwon HJ; Kim BS; Chung HC
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1901-13. PubMed ID: 20217129
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Effects of Valproic Acid Treatment on Cell Survival and Epithelial-Mesenchymal Transition-Related Features of Human Gastric Cancer Cells.
Jahani M; Khanahmad H; Nikpour P
J Gastrointest Cancer; 2021 Jun; 52(2):676-681. PubMed ID: 32621111
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of MS-275, a selective inhibitor of class I histone deacetylases, in human colon cancer models.
Bracker TU; Sommer A; Fichtner I; Faus H; Haendler B; Hess-Stumpp H
Int J Oncol; 2009 Oct; 35(4):909-20. PubMed ID: 19724929
[TBL] [Abstract][Full Text] [Related]
10. HDAC is indispensable for IFN-γ-induced B7-H1 expression in gastric cancer.
Deng R; Zhang P; Liu W; Zeng X; Ma X; Shi L; Wang T; Yin Y; Chang W; Zhang P; Wang G; Tao K
Clin Epigenetics; 2018 Dec; 10(1):153. PubMed ID: 30537988
[TBL] [Abstract][Full Text] [Related]
11. C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits.
Wang L; Yin J; Wang X; Shao M; Duan F; Wu W; Peng P; Jin J; Tang Y; Ruan Y; Sun Y; Gu J
Gastroenterology; 2016 May; 150(5):1183-1195.e16. PubMed ID: 26855187
[TBL] [Abstract][Full Text] [Related]
12. Tumor suppressor role of miR-133a in gastric cancer by repressing IGF1R.
Gong Y; Ren J; Liu K; Tang LM
World J Gastroenterol; 2015 Mar; 21(10):2949-58. PubMed ID: 25780292
[TBL] [Abstract][Full Text] [Related]
13. Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer.
Ivanova T; Zouridis H; Wu Y; Cheng LL; Tan IB; Gopalakrishnan V; Ooi CH; Lee J; Qin L; Wu J; Lee M; Rha SY; Huang D; Liem N; Yeoh KG; Yong WP; Teh BT; Tan P
Gut; 2013 Jan; 62(1):22-33. PubMed ID: 22535375
[TBL] [Abstract][Full Text] [Related]
14. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O
Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525
[TBL] [Abstract][Full Text] [Related]
15. Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems.
Chang HR; Park HS; Ahn YZ; Nam S; Jung HR; Park S; Lee SJ; Balch C; Powis G; Ku JL; Kim YH
BMC Cancer; 2016 Mar; 16():200. PubMed ID: 26955870
[TBL] [Abstract][Full Text] [Related]
16. Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth.
Ye J; Huang Q; Xu J; Huang J; Wang J; Zhong W; Chen W; Lin X; Lin X
J Cancer Res Clin Oncol; 2018 May; 144(5):821-833. PubMed ID: 29435734
[TBL] [Abstract][Full Text] [Related]
17. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
Stubbs MC; Kim W; Bariteau M; Davis T; Vempati S; Minehart J; Witkin M; Qi J; Krivtsov AV; Bradner JE; Kung AL; Armstrong SA
Clin Cancer Res; 2015 May; 21(10):2348-58. PubMed ID: 25688158
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
[TBL] [Abstract][Full Text] [Related]
19. 1,25(OH)
Huang J; Yang G; Huang Y; Zhang S
Biochimie; 2018 Mar; 146():28-34. PubMed ID: 29158005
[TBL] [Abstract][Full Text] [Related]
20. Valproic acid targets HDAC1/2 and HDAC1/PTEN/Akt signalling to inhibit cell proliferation via the induction of autophagy in gastric cancer.
Sun J; Piao J; Li N; Yang Y; Kim KY; Lin Z
FEBS J; 2020 May; 287(10):2118-2133. PubMed ID: 31692265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
